The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
